LUNG Financials: Pulmonx Corp AI Analysis



Financials

LUNG Financial

Pulmonx Corp

$1.61

28.8%

$0.36

At close: Jul 30, 16:00:00 GMT-4

$1.6

-0.59%

$0

Post-market: Jul 30, 17:35:17 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$1.25

Open

$1.4

Day's Range

$1.32 - $1.81

52 week range

$1.13 - $3.39

Volume

4.7M

Avg.Volume

433.8K

Dividend yield

EPS (TTM)

-1.29

Market Cap

$67.6M

What is LUNG?

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 296 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Features

Markets

News

Breakdown	TTM	03/31/2026	12/31/2025	09/30/2025	06/30/2025	03/31/2025
Revenue	88	20	22	21	23	22
Revenue Growth (YoY)	1%	-9%	-4%	5%	15%	22%
Cost of Revenue	21	4	5	5	6	6
Gross Profit	66	16	17	16	17	16
Selling, General & Admin	99	24	22	25	26	26
Research & Development	17	4	2	4	5	4
Operating Expenses	118	29	25	30	32	30
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-52	-13	-10	-13	-14	-14
Income Tax Expense	0	0	0	0	0	0
Net Income	-53	-13	-10	-13	-15	-14
Net Income Growth	-5%	-7%	-23%	-7%	0%	8%
Shares Outstanding (Diluted)	41.89	41.89	41.41	40.93	40.42	39.95
Shares Change (YoY)	5%	5%	5%	5%	4%	3%
EPS (Diluted)	-1.26	-0.32	-0.25	-0.34	-0.37	-0.36
EPS Growth	-11%	-10%	-24%	-5%	-4%	2%
Free Cash Flow	-29	-10	-7	-8	-3	-13
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	75%	80%	77.27%	76.19%	73.91%	72.72%
Operating Margin	-59.09%	-60%	-36.36%	-66.66%	-60.86%	-63.63%
Profit Margin	-60.22%	-65%	-45.45%	-61.9%	-65.21%	-63.63%
Free Cash Flow Margin	-32.95%	-50%	-31.81%	-38.09%	-13.04%	-59.09%
EBITDA	-52	-12	-8	-14	-14	-14
EBITDA Margin	-59.09%	-60%	-36.36%	-66.66%	-60.86%	-63.63%
D&A For EBITDA	0	0	0	0	0	0
EBIT	-52	-12	-8	-14	-14	-14
EBIT Margin	-59.09%	-60%	-36.36%	-66.66%	-60.86%	-63.63%
Effective Tax Rate	0%	0%	0%	0%	0%	0%

Breakdown

TTM

03/31/2026

12/31/2025

09/30/2025

06/30/2025

03/31/2025

Revenue

Revenue Growth (YoY)

-9%

-4%

15%

22%

Cost of Revenue

Gross Profit

Selling, General & Admin

Research & Development

Operating Expenses

118

Other Non Operating Income (Expenses)

Pretax Income

-52

-13

-10

-13

-14

Income Tax Expense

Net Income

-53

-13

-10

-13

-15

-14

Net Income Growth

-5%

-7%

-23%

-7%

Shares Outstanding (Diluted)

41.89

41.41

40.93

40.42

39.95

Shares Change (YoY)

EPS (Diluted)

-1.26

-0.32

-0.25

-0.34

-0.37

-0.36

EPS Growth

-11%

-10%

-24%

-5%

-4%

Free Cash Flow

-29

-10

-7

-8

-3

-13

Free Cash Flow Per Share

Gross Margin

75%

80%

77.27%

76.19%

73.91%

72.72%

Operating Margin

-59.09%

-60%

-36.36%

-66.66%

-60.86%

-63.63%

Profit Margin

-60.22%

-65%

-45.45%

-61.9%

-65.21%

-63.63%

Free Cash Flow Margin

-32.95%

-50%

-31.81%

-38.09%

-13.04%

-59.09%

EBITDA

-52

-12

-8

-14

EBITDA Margin

-59.09%

-60%

-36.36%

-66.66%

-60.86%

-63.63%

D&A For EBITDA

EBIT

-52

-12

-8

-14

EBIT Margin

-59.09%

-60%

-36.36%

-66.66%

-60.86%

-63.63%

Effective Tax Rate

Follow-Up Questions

What are Pulmonx Corp's key financial statements?



According to the latest financial statement (Form-10K), Pulmonx Corp has a total asset of $0, Net loss of $0

What are the key financial ratios for LUNG?



Pulmonx Corp's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is Pulmonx Corp's revenue broken down by segment or geography?



Pulmonx Corp largest revenue segment is Interventional Pulmonology, at a revenue of 90,497,000 in the most earnings release.For geography, United States is the primary market for Pulmonx Corp, at a revenue of 57,023,000.

Is Pulmonx Corp profitable?



no, according to the latest financial statements, Pulmonx Corp has a net loss of $0

Does Pulmonx Corp have any liabilities?



no, Pulmonx Corp has liability of 0

How many outstanding shares for Pulmonx Corp?



Pulmonx Corp has a total outstanding shares of 0

Pulmonx Corp (LUNG) Financial

LUNG Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is LUNG?

Pulmonx Corp (LUNG) Financial

LUNG Stock Price Chart

Key Stats

Prev.Close

Open

Day's Range

52 week range

Volume

Avg.Volume

Dividend yield

EPS (TTM)

Market Cap

What is LUNG?

LUNG Income

Follow-Up Questions

What are Pulmonx Corp's key financial statements?

What are the key financial ratios for LUNG?

How is Pulmonx Corp's revenue broken down by segment or geography?

Is Pulmonx Corp profitable?

Does Pulmonx Corp have any liabilities?

How many outstanding shares for Pulmonx Corp?